Glossary
|
Site map
|
Site tour
Home
Our company
Overview
News & events
Facts & Figures
Actelion worldwide
Company strategy
Actelion people
Corporate governance
Publications
History
Contact us
Healthcare professionals
Overview
Business Strategy & Operations
Products
Diseases
Scientific award
Contact us
Patients
Overview
Diseases
Clinical trials
Drug discovery & development
Understanding Drug Safety
Scientists
Overview
R&D approach
Therapeutic areas
Mechanisms of Action
Development pipeline
Contact us
Journalists
Overview
Latest News
News archive
At a glance
Image library
Media kit
Medieninformationen
Stay informed
Contact us
Investors
Overview
Results Day Center
Financial information
Media releases
Stock information
First-time investor
Events
Stay informed
Contact us
Applicants
Overview
Job opportunities
Career development
Rewards & benefits
Growth at Actelion
You are here:
Home
> Site map
Site map
Our company
Overview
News & events
Facts & Figures
Actelion worldwide
Company strategy
Our values
Partnerships & collaborations
In-licensing
Partnerships
Acquisitions
Actelion people
Founders
Board of Directors
Senior management
Scientific Advisory Board
Corporate structure
Corporate governance
Corporate responsibility
Health, safety and environment
Patient advocacy
Publications
Annual Report archive
History
Contact us
Stay informed
Healthcare professionals
Overview
Business Strategy & Operations
Products
Tracleer®
Pediatric formulation
Current indications
Safety information
Product availability and regulatory status
Clinical data
Congresses
Key scientific literature
Ventavis®
Current indications
Safety information
Clinical data
Product availability and regulatory status
Key scientific literature
Epoprostenol for injection
Formulated for improved stability
Current indications
Safety information
Product availability & regulatory status
Clinical data
Key scientific literature
Zavesca®
Current indications
Safety information
Product availability and regulatory status
Clinical data
Congresses
Key scientific literature
Diseases
Pulmonary arterial hypertension (PAH)
What is PAH?
How is PAH diagnosed?
How can PAH be treated?
What is pediatric PAH?
How is pediatric PAH diagnosed?
How can pediatric PAH be treated?
Clinical activities
Further information
Digital ulcers (DU)
How is DU diagnosed?
How can DU be treated?
Clinical activities
Further information
Type 1 Gaucher disease (GD1)
How is GD1 diagnosed?
How can GD1 be treated?
Further information
Niemann-Pick type C (NP-C)
How is NP-C diagnosed?
How can NP-C be treated?
Further information
Scientific award
Contact us
Patients
Overview
Diseases
Pulmonary arterial hypertension (PAH)
What is PAH?
How is PAH diagnosed?
How can PAH be treated?
What is pediatric PAH?
How is pediatric PAH diagnosed?
How can pediatric PAH be treated?
Further information
Digital ulcers (DU)
How is DU diagnosed?
How can DU be treated?
Further information
Type 1 Gaucher disease (GD1)
What is Gaucher disease?
How is GD1 diagnosed?
How can GD1 be treated?
Further information
Niemann-Pick type C (NP-C)
What is NP-C?
How is NP-C diagnosed?
How can NP-C be treated?
Further information
Clinical trials
Drug discovery & development
Understanding Drug Safety
Scientists
Overview
R&D approach
Drug discovery process
Molecular cell biology
Biochemistry
Chemistry
Research informatics
Molecular modeling & structural biology
Pharmacology
Pharmacokinetics & metabolism
Process research chemistry
Preformulation & formulation
Platform approach
New chemical entities
G-Protein coupled receptors
Enzymes
Ion channels
Anti-infectives
Project selection
Development process
Therapeutic areas
Cardiovascular disorders
PAH
DU
IPF
aSAH
Central nervous system
Sleep disorders
What is normal sleep?
Alzheimer's disease
Genetic disorders
GD1
NP-C
Cystic fibrosis
Immunology
Allergy
What is the allergic response?
Asthma
MS
Psoriasis
Infectious diseases
Oncology
Mechanisms of Action
Endothelin receptor antagonism
The endothelium
Endothelin system
Prostacyclin receptor agonism
The endothelium
Prostacyclin system
Substrate reduction therapy
Orexin receptor antagonism
CRTH2 receptor antagonism
S1P1 receptor agonism
S1P system
Renin inhibition
BACE-1 inhibition
Development pipeline
Phase IV
Bosentan (Tracleer®)
Miglustat (Zavesca®)
Phase III
Almorexant
Clazosentan
Macitentan
Olesoxime
Selexipag
Phase II
Anti-infective
CRTH2 antagonist
Macitentan
S1P1 agonist
Phase I
Cardiovascular
Contact us
Investors
Overview
Results Day Center
Financial information
Marketed products
Tracleer® sales
Ventavis® sales
Zavesca® sales
Finance archive
Media releases
Stock information
Stock tools
Analysts coverage
First-time investor
How to buy stock
Investor glossary
FAQ
Events
AGM
AGM archive
Investor audiocast
Media and Analyst Day 2010
IR roadshows
Stay informed
Contact us
Journalists
Overview
Latest News
Latest news 1
Latest news 2
News archive
At a glance
Image library
Media kit
Medieninformationen
Stay informed
Contact us
Applicants
Overview
Job opportunities
Current vacancies
Diversity
Privacy policy
Career development
Rewards & benefits
Growth at Actelion
Actelion.com
Home
Site tour
Site map
Glossary
Imprint
Legal & privacy statement
